Sanofi Pasteur Acquires Exclusive, Worldwide License for Acne Vaccine

[Guest guest]

good grief

http://www.fiercebiotech.com/press-releases/sanofi-pasteur-acquires-exclusive-worldwide-license-acne-vaccine-and-treatm

Sanofi Pasteur Acquires Exclusive, Worldwide License for Acne

Vaccine and Treatment- The pre-clinical vaccine was developed by

researchers at the University of California, San Diego -

Read more:

Sanofi Pasteur Acquires Exclusive, Worldwide License for Acne Vaccine and

Treatment- The pre-clinical vaccine was developed by r -

FierceBiotech

http://www.fiercebiotech.com/press-releases/sanofi-pasteur-acquires-exclusive-worldwide-license-acne-vaccine-and-treatm#ixzz1Yl4h8qmj

Subscribe:

http://www.fiercebiotech.com/signup?sourceform=Viral-Tynt-FierceBiotech-FierceBiotech

Posted September 21, 2011

Sanofi Pasteur Acquires Exclusive, Worldwide License for Acne Vaccine

and Treatment- The pre-clinical vaccine was developed by researchers at

the University of California, San Diego -

Lyon, France - September 21, 2011 - Sanofi Pasteur, the vaccines

division of Sanofi (EURONEXT: SAN and NYSE: SNY), announced today a

research and development collaboration with the University of California,

San Diego (UC San Diego) on an immunological approach to acne prevention

and treatment targeting the specific neutralization of Propionibacterium

acnes factors in inflammation.

Sign up for our FREE newsletter for more news like this sent to your

inbox!

Acne vulgaris (acne) is one of the most common skin diseases worldwide

and affects more than 50 million people in the United States alone.1 The

disease has multiple, complex factors and is associated in particular

with the Gram-positive anaerobic bacterium P. acnes that is a normal

member of the human skin microflora.2 Current treatment of mild forms of

acne involves killing P. acnes with bactericidal agents such as benzoyl

peroxide and oral or topical antibiotics, all of which indiscriminately

kill many bacterial species and disrupt the normal balance of the skin

microflora.3 Long-term use of antibiotics also leads to resistant strains

of P. acnes.4

" This opportunity could provide an immunotherapeutic product with

significant benefits and a novel mechanism of action to address an unmet

medical need, " according to Elias Zerhouni, M.D., President, Global

Research & Development, Sanofi. " This investigational vaccine

and treatment may lead to a better solution for the many who suffer from

this skin disease. "

According to Sanofi Pasteur's estimates, the annual worldwide market for

acne therapeutics is in excess of US $3 billion. The financial terms of

the agreement were not disclosed. The agreement includes a two-year

research collaboration with Dr. Chun-Ming Huang and his associates at UC

San Diego School of Medicine for further research and

development.

About Acne5,6,7

Acne is an extremely common multi-factorial skin disease with a

prevalence of 80 to 90 percent in adolescents. The disease sometimes

continues through the teenage years; eight percent of 25 to

34-year olds and three percent of 35 to 44-year-old people continue to

suffer from the disease. Moderate to severe acne occurs in 14 percent of

five to 17-year olds and this group is more likely to seek treatment and

currently faces an unmet medical need. Acne is considered a chronic

disease for a limited life-time period and, although often a simple and

self-limited condition, it can result in psychological, physical and

social implications.

About Sanofi

Sanofi, a global and diversified healthcare leader, discovers, develops

and distributes therapeutic solutions focused on patients' needs. Sanofi

has core strengths in the field of healthcare with seven growth

platforms: diabetes solutions, human vaccines, innovative drugs, rare

diseases, consumer healthcare, emerging markets and animal health. Sanofi

is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Sanofi Pasteur, the vaccines division of Sanofi, provides more than 1

billion doses of vaccine each year, making it possible to immunize more

than 500 million people across the globe. A world leader in the vaccine

industry, Sanofi Pasteur offers the broadest range of vaccines protecting

against 20 infectious diseases. The company's heritage, to create

vaccines that protect life, dates back more than a century. Sanofi

Pasteur is the largest company entirely dedicated to vaccines. Every day,

the company invests more than EUR 1 million in research and development.

For more information, please visit:

www.sanofipasteur.com or

www.sanofipasteur.us

Forward Looking Statements

This press release contains forward-looking statements as defined in the

Private Securities Litigation Reform Act of 1995, as amended.

Forward-looking statements are statements that are not historical facts.

These statements include projections and estimates and their underlying

assumptions, statements regarding plans, objectives, intentions and

expectations with respect to future financial results, events,

operations, services, product development and potential, and statements

regarding future performance. Forward-looking statements are generally

identified by the words " expects " , " anticipates " ,

" believes " , " intends " , " estimates " ,

" plans " and similar expressions. Although Sanofi's management

believes that the expectations reflected in such forward-looking

statements are reasonable, investors are cautioned that forward-looking

information and statements are subject to various risks and

uncertainties, many of which are difficult to predict and generally

beyond the control of Sanofi, that could cause actual results and

developments to differ materially from those expressed in, or implied or

projected by, the forward-looking information and statements. These risks

and uncertainties include among other things, the uncertainties inherent

in research and development, future clinical data and analysis, including

post marketing, decisions by regulatory authorities, such as the FDA or

the EMA, regarding whether and when to approve any drug, device or

biological application that may be filed for any such product candidates

as well as their decisions regarding labeling and other matters that

could affect the availability or commercial potential of such products

candidates, the absence of guarantee that the products candidates if

approved will be commercially successful, the future approval and

commercial success of therapeutic alternatives, the Group's ability to

benefit from external growth opportunities as well as those discussed or

identified in the public filings with the SEC and the AMF made by Sanofi,

including those listed under " Risk Factors " and

" Cautionary Statement Regarding Forward-Looking Statements " in

Sanofi's annual report on Form 20-F for the year ended December 31, 2010.

Other than as required by applicable law, Sanofi does not undertake any

obligation to update or revise any forward-looking information or

statements.

Read more:

Sanofi Pasteur Acquires Exclusive, Worldwide License for Acne Vaccine and

Treatment- The pre-clinical vaccine was developed by r -

FierceBiotech

http://www.fiercebiotech.com/press-releases/sanofi-pasteur-acquires-exclusive-worldwide-license-acne-vaccine-and-treatm#ixzz1Yl4Yy5Q6

Subscribe:

http://www.fiercebiotech.com/signup?sourceform=Viral-Tynt-FierceBiotech-FierceBiotech

Sheri Nakken, former R.N., MA, Hahnemannian

Homeopath

Vaccination Information & Choice Network, Washington State, USA

Vaccines -

http://vaccinationdangers.wordpress.com/ Homeopathy

http://homeopathycures.wordpress.com

Vaccine Dangers, Childhood Disease Classes & Homeopathy

Online/email courses - next classes start September 9

[Guest guest]

good grief

http://www.fiercebiotech.com/press-releases/sanofi-pasteur-acquires-exclusive-worldwide-license-acne-vaccine-and-treatm

Sanofi Pasteur Acquires Exclusive, Worldwide License for Acne

Vaccine and Treatment- The pre-clinical vaccine was developed by

researchers at the University of California, San Diego -

Read more:

Sanofi Pasteur Acquires Exclusive, Worldwide License for Acne Vaccine and

Treatment- The pre-clinical vaccine was developed by r -

FierceBiotech

http://www.fiercebiotech.com/press-releases/sanofi-pasteur-acquires-exclusive-worldwide-license-acne-vaccine-and-treatm#ixzz1Yl4h8qmj

Subscribe:

http://www.fiercebiotech.com/signup?sourceform=Viral-Tynt-FierceBiotech-FierceBiotech

Posted September 21, 2011

Sanofi Pasteur Acquires Exclusive, Worldwide License for Acne Vaccine

and Treatment- The pre-clinical vaccine was developed by researchers at

the University of California, San Diego -

Lyon, France - September 21, 2011 - Sanofi Pasteur, the vaccines

division of Sanofi (EURONEXT: SAN and NYSE: SNY), announced today a

research and development collaboration with the University of California,

San Diego (UC San Diego) on an immunological approach to acne prevention

and treatment targeting the specific neutralization of Propionibacterium

acnes factors in inflammation.

Sign up for our FREE newsletter for more news like this sent to your

inbox!

Acne vulgaris (acne) is one of the most common skin diseases worldwide

and affects more than 50 million people in the United States alone.1 The

disease has multiple, complex factors and is associated in particular

with the Gram-positive anaerobic bacterium P. acnes that is a normal

member of the human skin microflora.2 Current treatment of mild forms of

acne involves killing P. acnes with bactericidal agents such as benzoyl

peroxide and oral or topical antibiotics, all of which indiscriminately

kill many bacterial species and disrupt the normal balance of the skin

microflora.3 Long-term use of antibiotics also leads to resistant strains

of P. acnes.4

" This opportunity could provide an immunotherapeutic product with

significant benefits and a novel mechanism of action to address an unmet

medical need, " according to Elias Zerhouni, M.D., President, Global

Research & Development, Sanofi. " This investigational vaccine

and treatment may lead to a better solution for the many who suffer from

this skin disease. "

According to Sanofi Pasteur's estimates, the annual worldwide market for

acne therapeutics is in excess of US $3 billion. The financial terms of

the agreement were not disclosed. The agreement includes a two-year

research collaboration with Dr. Chun-Ming Huang and his associates at UC

San Diego School of Medicine for further research and

development.

About Acne5,6,7

Acne is an extremely common multi-factorial skin disease with a

prevalence of 80 to 90 percent in adolescents. The disease sometimes

continues through the teenage years; eight percent of 25 to

34-year olds and three percent of 35 to 44-year-old people continue to

suffer from the disease. Moderate to severe acne occurs in 14 percent of

five to 17-year olds and this group is more likely to seek treatment and

currently faces an unmet medical need. Acne is considered a chronic

disease for a limited life-time period and, although often a simple and

self-limited condition, it can result in psychological, physical and

social implications.

About Sanofi

Sanofi, a global and diversified healthcare leader, discovers, develops

and distributes therapeutic solutions focused on patients' needs. Sanofi

has core strengths in the field of healthcare with seven growth

platforms: diabetes solutions, human vaccines, innovative drugs, rare

diseases, consumer healthcare, emerging markets and animal health. Sanofi

is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Sanofi Pasteur, the vaccines division of Sanofi, provides more than 1

billion doses of vaccine each year, making it possible to immunize more

than 500 million people across the globe. A world leader in the vaccine

industry, Sanofi Pasteur offers the broadest range of vaccines protecting

against 20 infectious diseases. The company's heritage, to create

vaccines that protect life, dates back more than a century. Sanofi

Pasteur is the largest company entirely dedicated to vaccines. Every day,

the company invests more than EUR 1 million in research and development.

For more information, please visit:

www.sanofipasteur.com or

www.sanofipasteur.us

Forward Looking Statements

This press release contains forward-looking statements as defined in the

Private Securities Litigation Reform Act of 1995, as amended.

Forward-looking statements are statements that are not historical facts.

These statements include projections and estimates and their underlying

assumptions, statements regarding plans, objectives, intentions and

expectations with respect to future financial results, events,

operations, services, product development and potential, and statements

regarding future performance. Forward-looking statements are generally

identified by the words " expects " , " anticipates " ,

" believes " , " intends " , " estimates " ,

" plans " and similar expressions. Although Sanofi's management

believes that the expectations reflected in such forward-looking

statements are reasonable, investors are cautioned that forward-looking

information and statements are subject to various risks and

uncertainties, many of which are difficult to predict and generally

beyond the control of Sanofi, that could cause actual results and

developments to differ materially from those expressed in, or implied or

projected by, the forward-looking information and statements. These risks

and uncertainties include among other things, the uncertainties inherent

in research and development, future clinical data and analysis, including

post marketing, decisions by regulatory authorities, such as the FDA or

the EMA, regarding whether and when to approve any drug, device or

biological application that may be filed for any such product candidates

as well as their decisions regarding labeling and other matters that

could affect the availability or commercial potential of such products

candidates, the absence of guarantee that the products candidates if

approved will be commercially successful, the future approval and

commercial success of therapeutic alternatives, the Group's ability to

benefit from external growth opportunities as well as those discussed or

identified in the public filings with the SEC and the AMF made by Sanofi,

including those listed under " Risk Factors " and

" Cautionary Statement Regarding Forward-Looking Statements " in

Sanofi's annual report on Form 20-F for the year ended December 31, 2010.

Other than as required by applicable law, Sanofi does not undertake any

obligation to update or revise any forward-looking information or

statements.

Read more:

Sanofi Pasteur Acquires Exclusive, Worldwide License for Acne Vaccine and

Treatment- The pre-clinical vaccine was developed by r -

FierceBiotech

http://www.fiercebiotech.com/press-releases/sanofi-pasteur-acquires-exclusive-worldwide-license-acne-vaccine-and-treatm#ixzz1Yl4Yy5Q6

Subscribe:

http://www.fiercebiotech.com/signup?sourceform=Viral-Tynt-FierceBiotech-FierceBiotech

Sheri Nakken, former R.N., MA, Hahnemannian

Homeopath

Vaccination Information & Choice Network, Washington State, USA

Vaccines -

http://vaccinationdangers.wordpress.com/ Homeopathy

http://homeopathycures.wordpress.com

Vaccine Dangers, Childhood Disease Classes & Homeopathy

Online/email courses - next classes start September 9